What Role will Ensifentrine Play in the Future Treatment of Chronic Obstructive Pulmonary Disease Patients? Implications from Recent Clinical Trials

References

• Boswell-Smith V , SpinaD , OxfordAW , ComerMB , SeedsEA , PageCP. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. J. Pharmacol. Exp. Ther.318(2), 840–848 (2006).
   PubMed Web of Science ®Google Scholar
• Cazzola M , PageC. An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD. Eur. Respir. J.52(5), 1801675 (2018).
   Web of Science ®Google Scholar
• Page CP . Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Int. Arch. Allergy Immunol.165(3), 152–164 (2014).
   PubMed Web of Science ®Google Scholar
• Schmidt DT , WatsonN , DentGet al. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitised human airways. Br. J. Pharmacol.131(8), 1607–1618 (2000).
   PubMed Web of Science ®Google Scholar
• Abbott-Banner KH , PageCP. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. Basic Clin. Pharmacol. Toxicol.114, 365–376 (2014).
   PubMed Web of Science ®Google Scholar
• Beute J , LukkesM , KoekoekEPet al. A pathophysiological role of PDE3 in allergic airway inflammation. JCI Insight.3(2), e94888 (2018).
   PubMed Web of Science ®Google Scholar
• Cobb BR , FanL , KovacsTE , SorscherEJ , ClancyJP. Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am. J. Respir. Cell Mol. Biol.29(3 Pt 1), 410–418 (2003).
   PubMed Web of Science ®Google Scholar
• Barnes AP , LiveraG , HuangPet al. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J. Biol. Chem.280(9), 7997–8003 (2005).
   PubMed Web of Science ®Google Scholar
• Page C , CazzolaM. Bifunctional drugs for the treatment of respiratory diseases. Handb. Exp. Pharmacol.237, 197–212 (2017).
   PubMedGoogle Scholar
• Cazzola M , PageC , CalzettaL , MateraMG. Ensifentrine (RPL554): an inhaled ‘bifunctional’ dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Pharm. Pat. Anal.7(6), 249–257 (2018).
   PubMed Web of Science ®Google Scholar
• Cazzola M , CalzettaL , RoglianiP , MateraMG. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin. Investig. Drugs.28(10), 827–833 (2019).
   PubMed Web of Science ®Google Scholar
• Donohue JF , RheaultT , MacDonald-BerkoM , BengtssonT , RickardK. Ensifentrine as a novel, inhaled treatment for patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis.18, 1611–1622 (2023).
   PubMed Web of Science ®Google Scholar
• Calzetta L , PageCP , SpinaDet al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J. Pharmacol. Exp. Ther.346(3), 414–423 (2013).
   PubMed Web of Science ®Google Scholar
• Calzetta L , CazzolaM , PageCP , RoglianiP , FaccioloF , MateraMG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm. Pharmacol. Ther.32, 15–23 (2015).
   PubMed Web of Science ®Google Scholar
• Venkatasamy R , SpinaD. Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility. Br. J. Pharmacol.173(15), 2335–2351 (2016).
   PubMed Web of Science ®Google Scholar
• Franciosi LG , DiamantZ , BannerKHet al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir. Med.1(9), 714–727 (2013).
   PubMed Web of Science ®Google Scholar
• Turner MJ , MatthesE , BilletAet al. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol.310(1), L59–L70 (2016).
   PubMed Web of Science ®Google Scholar
• Cazzola M , PageC , MateraMG. Ensifentrine: A first-in-class bifunctional drug for the treatment of chronic obstructive pulmonary disease. etouchREVIEWS Respir. Pulmon. Dis.7(2), 48–53 (2022).
   Google Scholar
• Rickard K , RheaultT , BengtssonT. Twice-daily, nebulized ensifentrine produced significant improvement in week 12 lung function: subgroup analysis in the phase 3 trial ENHANCE-2. Am. J. Respir. Crit. Care Med.207, A2838 (2023).
   Web of Science ®Google Scholar
• Barjaktarevic IZ , RheaultT , BengtssonT , RickardK. Ensifentrine reduced healthcare resource utilization in subjects with COPD: results from ENHANCE-2, a phase 3 trial of ensifentrine, a dual PDE3/4 inhibitor. Am. J. Respir. Crit. Care Med.207, A2839 (2023).
   Web of Science ®Google Scholar
• Anzueto A , RheaultT , BengtssonT , RickardK. Treatment with ensifentrine, a dual PDE3 and PDE4 inhibitor, significantly reduced exacerbation rate and risk in subjects with COPD: sub-group results from the phase 3 trial, ENHANCE-2. Am. J. Respir. Crit. Care Med.207, A4998 (2023).
   Web of Science ®Google Scholar
• Ferguson GT , RheaultT , BengtssonT , RickardK. Ensifentrine, a dual inhibitor of PDE3 and PDE4, reduces the risk of exacerbation regardless of background medication use: a sub-group analysis of ENHANCE-2, a phase 3 trial. Am. J. Respir. Crit. Care Med.207, A4999 (2023).
   Web of Science ®Google Scholar
• Rheault T , BengtssonT , RickardK. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, in moderate and severe COPD: symptoms, quality of life and health status from the phase 3 trial ENHANCE-2. Am. J. Respir. Crit. Care Med.207, A5000 (2023).
   Web of Science ®Google Scholar
• Siler TM , RickardK , BengtssonT , RheaultT. Safety results from dual PDE3/4 inhibitor ensifentrine: gastrointestinal and cardiovascular safety from a 24-week phase 3 trial, ENHANCE-2. Am. J. Respir. Crit. Care Med.207, A5003 (2023).
   Web of Science ®Google Scholar
• Siler TM , RheaultT , BengtssonT , RickardK. Twice-daily, nebulized ensifentrine significantly improves lung function: sub-group analysis in the phase 3 trial, ENHANCE-1. Am. J. Respir. Crit. Care Med.207, A5004 (2023).
   Web of Science ®Google Scholar
• Sciurba F , WiseR , RheaultT , BengtssonT , RickardK. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, improves lung function, symptoms, quality of life and reduces exacerbation rate and risk in the ENHANCE-1 phase 3 trial of ensifentrine in COPD. Am. J. Respir. Crit. Care Med.207, A5006 (2023).
   Web of Science ®Google Scholar
• Sciurba F , RheaultT , BengtssonT , RickardK. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, significantly improves COPD symptoms and quality of life in the phase 3 ENHANCE-1 trial. Am. J. Respir. Crit. Care Med.207, A5007 (2023).
   Web of Science ®Google Scholar
• Barjaktarevic IZ , RheaultT , BengtssonT , RickardK. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, significantly reduces annualized exacerbations and delays the time to first exacerbation in COPD: pooled sub-group analyses of ENHANCE-1 and ENHANCE-2 phase 3 trials. Am. J. Respir. Crit. Care Med.207, A5008 (2023).
   Web of Science ®Google Scholar
• Sciurba F , AnzuetoA , RheaultT , BengtssonT , RickardK. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, improves lung function, symptoms, quality of life and reduces exacerbation rate and risk in patients with COPD: results from replicate phase 3 trials. Am. J. Respir. Crit. Care Med.207, A5005 (2023).
   Web of Science ®Google Scholar
• Anzueto A , BarjaktarevicIZ , SilerTMet al. Ensifentrine, a novel PDE3 and PDE4 inhibitor for the treatment of COPD: randomized, double-blind, placebo-controlled, multicenter, phase III trials (the ENHANCE trials). Am. J. Respir. Crit. Care Med.208(4), 406–416 (2023).
   PubMed Web of Science ®Google Scholar
• Jensen B . Verona Pharma: Targeting the large COPD market (2023). https://seekingalpha.com/article/4625531-verona-pharma-targeting-the-large-copd-market?mailingid=32348864&messageid=must_reads&serial=32348864.3878154&utm_campaign=Must%2BReads%2Brecurring%2B2023-08-09&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads
   Google Scholar
• Singh D , Abbott-BannerK , BengtssonT , NewmanK. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur. Respir. J.52(5), 1801074 (2018).
   PubMed Web of Science ®Google Scholar
• Singh D , MartinezFJ , WatzH , BengtssonT , MaurerBT. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respir. Res.21(1), 47 (2020).
   PubMed Web of Science ®Google Scholar
• Rickard K , RheaultT , BengtssonT. Additional bronchodilation by ensifentrine, a dual PDE3/4 inhibitor, when combined with a LAMA/LABA in patients with moderate to severe COPD. Am. J. Respir. Crit. Care Med.201, A4298 (2020).
   Web of Science ®Google Scholar
• Agustí A , CelliBR , CrinerGJet al. Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary. Eur. Respir. J.61(4), 2300239 (2023).
   PubMed Web of Science ®Google Scholar
• Cazzola M , HananiaNA , PageCP , MateraMG. Novel anti-inflammatory approaches to COPD. Int. J. Chron. Obstruct. Pulmon. Dis.18, 1333–1352 (2023).
   PubMed Web of Science ®Google Scholar
• Cazzola M , OraJ , CalzettaL , RoglianiP , MateraMG. Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today?Expert Opin. Pharmacother.23(8), 917–927 (2022).
   PubMed Web of Science ®Google Scholar
• Calzetta L , CoppolaA , RitondoBL , MatinoM , ChettaA , RoglianiP. The impact of muscarinic receptor antagonists on airway inflammation: a systematic review. Int. J. Chron. Obstruct. Pulmon. Dis.16, 257–279 (2021).
   PubMed Web of Science ®Google Scholar
• Beeh KM , BurgelPR , FranssenFMEet al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 196(2), 139–149 (2017).
   PubMed Web of Science ®Google Scholar
• Rab A , RoweSM , RajuSV , BebokZ , MatalonS , CollawnJF. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am. J. Physiol. Lung Cell. Mol. Physiol.305(8), L530–L541 (2013).
   PubMed Web of Science ®Google Scholar
• Mall MA , HartlD. CFTR: cystic fibrosis and beyond. Eur. Respir. J.44(4), 1042–1054 (2014).
   PubMed Web of Science ®Google Scholar
• Turner MJ , MatthesE , BilletAet al. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol.310(1), L59–L70 (2016).
   PubMed Web of Science ®Google Scholar
• Bjermer L , Abbott-BannerK , NewmanK. Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. Pulm. Pharmacol. Ther.58, 101814 (2019).
   PubMed Web of Science ®Google Scholar
• Turner MJ , Abbott-BannerK , ThomasDY , HanrahanJW. Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis. Pharmacol. Ther.224, 107826 (2021).
   PubMed Web of Science ®Google Scholar